D STATES PATENT AND TRA MARK OFFICE IN THE UNI

Elazar Rabbani et al. Applicants:

08/978,636 Serial No.

November 25, 1997 Filed:

NON-NATIVE POLYMERASE ENCODING Title

NUCLEIC ACID CONSTRUCT (As

Previously Amended)

Group Art Unit: 1635

Examiner Mary M. Schmidt

527 Madison Avenue, 9th Floor New York, New York 10022 August 18, 1999

FILED BY FIRST CLASS MAIL

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Attention: Box Sequence

SECOND AMENDMENT IN CONNECTION WITH NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES UNDER 37 C.F.R. §§1.821-1.825

Dear Sirs:

Applicants are submitting this Second Amendment in connection with the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures referenced in the Office Action issued February 18, 1999 in connection with the instant application. While Applicants copy of the aforementioned Office Action did not contain the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, Applicants are nevertheless submitting this Amendment pursuant to the requirements of the Notice

PLEASE AMEND THIS APPLICATION AS FOLLOWS:

In the Specification:

Page 23, after the last paragraph, kindly replace the sequence listing with the attached 13 pages inserted directly after this page and before page 24.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner of Patents & Trademarks Washington. 10231

Ronald C Fedus

AUG Date

ENZ-53(D3)

Elazar Rabbani et a. Serial No. 08/978,636 Filed: November 25, 1997

Page 2 (Second Amendment In Connection With Notice To Comply William Requirements For Patent Application Containing Nucleotide Se August 18, 1999)

REMARKS

By this Second Amendment applicants are directing the entry of the pa of the accompanying "Sequence Listing" into the instant specification, thereby conforming with one of the requirements of the Notice To Comply With Sequen Listing, that should have been attached to the February 18, 1999 OfficeAction is connection with this application.

No fee is believed due in connection with this Amendment. If any ee or fee due, however, the Patent and Trademark Office is hereby authorized to carge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Amendment, the undersigned may be contacted I telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,

Ronald C. Fedus Registration No. 32,567 Attorney for Applicants

ENZO THERAPEUTICS, INC c/o Enzo Biochem, Inc. 527 Madison Avenue (9th Fl.) New York, New York 10022 (212) 583-0100

LC\USPros\ENZ53(D3)\secondamendmentresequence 081899 enz53D3

BEST AVAILABLE COPY